IL249058B2 - Improved forms of selective pi3k delta inhibitors for use in pharmaceutical formulations - Google Patents

Improved forms of selective pi3k delta inhibitors for use in pharmaceutical formulations

Info

Publication number
IL249058B2
IL249058B2 IL249058A IL24905816A IL249058B2 IL 249058 B2 IL249058 B2 IL 249058B2 IL 249058 A IL249058 A IL 249058A IL 24905816 A IL24905816 A IL 24905816A IL 249058 B2 IL249058 B2 IL 249058B2
Authority
IL
Israel
Prior art keywords
salt
disease
lymphoma
tgr
disorder
Prior art date
Application number
IL249058A
Other languages
English (en)
Hebrew (he)
Other versions
IL249058B (en
IL249058A0 (en
Inventor
Swaroop Kumar Venkata Satya Vakkalanka
Original Assignee
Rhizen Pharmaceuticals Sa
Swaroop Kumar Venkata Satya Vakkalanka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals Sa, Swaroop Kumar Venkata Satya Vakkalanka filed Critical Rhizen Pharmaceuticals Sa
Publication of IL249058A0 publication Critical patent/IL249058A0/en
Publication of IL249058B publication Critical patent/IL249058B/en
Publication of IL249058B2 publication Critical patent/IL249058B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL249058A 2014-05-27 2016-11-20 Improved forms of selective pi3k delta inhibitors for use in pharmaceutical formulations IL249058B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2597CH2014 2014-05-27
IN2596CH2014 2014-05-27
PCT/IB2015/053940 WO2015181728A1 (en) 2014-05-27 2015-05-26 Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations

Publications (3)

Publication Number Publication Date
IL249058A0 IL249058A0 (en) 2017-01-31
IL249058B IL249058B (en) 2022-11-01
IL249058B2 true IL249058B2 (en) 2023-03-01

Family

ID=53499042

Family Applications (1)

Application Number Title Priority Date Filing Date
IL249058A IL249058B2 (en) 2014-05-27 2016-11-20 Improved forms of selective pi3k delta inhibitors for use in pharmaceutical formulations

Country Status (22)

Country Link
US (4) US9969740B2 (2)
EP (2) EP3149000B1 (2)
JP (3) JP6987501B2 (2)
KR (1) KR20170007480A (2)
CN (2) CN106661030B (2)
AU (1) AU2015265542B2 (2)
BR (1) BR112016027674A2 (2)
CA (1) CA2949932C (2)
CY (1) CY1124316T1 (2)
DK (1) DK3149000T3 (2)
EA (1) EA032506B1 (2)
ES (1) ES2880999T3 (2)
HR (1) HRP20211151T1 (2)
HU (1) HUE054916T2 (2)
IL (1) IL249058B2 (2)
LT (1) LT3149000T (2)
PL (1) PL3149000T3 (2)
PT (1) PT3149000T (2)
RS (1) RS62136B1 (2)
SI (1) SI3149000T1 (2)
SM (1) SMT202100532T1 (2)
WO (1) WO2015181728A1 (2)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015265542B2 (en) * 2014-05-27 2019-05-09 Rhizen Pharmaceuticals Sa Improved forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
EP3463318A4 (en) 2016-05-27 2020-01-01 TG Therapeutics Inc. COMBINATION OF ANTI-CD20-ANTIBODIES, P13-KINASE-DELTA-SELECTIVE INHIBITOR AND BTK-INHIBITOR FOR THE TREATMENT OF PROLIFERATIVE B-CELL DISORDERS
WO2018049263A1 (en) 2016-09-09 2018-03-15 Tg Therapeutics, Inc. Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
KR20220035169A (ko) * 2019-07-15 2022-03-21 존슨 맛쎄이 퍼블릭 리미티드 컴파니 비정질 움브랄리십 모노토실레이트
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014006572A1 (en) * 2012-07-04 2014-01-09 Rhizen Pharmaceuticals Sa Selective pi3k delta inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20084317B (en) * 2000-04-25 2008-02-25 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
KR20160091440A (ko) 2008-11-13 2016-08-02 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
BRPI1012333A2 (pt) 2009-03-24 2016-03-29 Gilead Calistoga Llc atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
AP2011005956A0 (en) 2009-04-20 2011-10-31 Gilead Calistoga Llc Methods of treatment for solid tumors.
AU2015265542B2 (en) * 2014-05-27 2019-05-09 Rhizen Pharmaceuticals Sa Improved forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014006572A1 (en) * 2012-07-04 2014-01-09 Rhizen Pharmaceuticals Sa Selective pi3k delta inhibitors

Also Published As

Publication number Publication date
JP2022082680A (ja) 2022-06-02
CA2949932C (en) 2021-08-10
US20210269446A1 (en) 2021-09-02
EA201692255A1 (ru) 2017-04-28
EP3149000B1 (en) 2021-06-30
SI3149000T1 (sl) 2021-09-30
CY1124316T1 (el) 2022-07-22
ES2880999T3 (es) 2021-11-26
RS62136B1 (sr) 2021-08-31
IL249058B (en) 2022-11-01
DK3149000T3 (da) 2021-08-30
US20170121336A1 (en) 2017-05-04
US20190016725A1 (en) 2019-01-17
CN111635406A (zh) 2020-09-08
KR20170007480A (ko) 2017-01-18
US9969740B2 (en) 2018-05-15
CA2949932A1 (en) 2015-12-03
HUE054916T2 (hu) 2021-10-28
AU2015265542B2 (en) 2019-05-09
AU2015265542A1 (en) 2016-12-08
CN106661030A (zh) 2017-05-10
JP2020122022A (ja) 2020-08-13
EA032506B1 (ru) 2019-06-28
IL249058A0 (en) 2017-01-31
JP2017516785A (ja) 2017-06-22
EP3971188A1 (en) 2022-03-23
US10947244B2 (en) 2021-03-16
WO2015181728A1 (en) 2015-12-03
PL3149000T3 (pl) 2021-11-02
CN106661030B (zh) 2020-06-30
EP3149000A1 (en) 2017-04-05
SMT202100532T1 (it) 2021-11-12
PT3149000T (pt) 2021-07-27
JP6987501B2 (ja) 2022-01-05
BR112016027674A2 (pt) 2017-08-15
LT3149000T (lt) 2021-09-10
US10414773B2 (en) 2019-09-17
US20190382411A1 (en) 2019-12-19
HRP20211151T1 (hr) 2021-10-15

Similar Documents

Publication Publication Date Title
US10414773B2 (en) Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
EP3153170B1 (en) Methods and uses of the quinoline derivative anlotinib in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same
JP2024533423A (ja) 薬学的組成物およびその使用
TW201442712A (zh) 有機化合物之調配物
CN109988104B (zh) 山奈酚与异烟酰胺共晶物及制备方法和其药物组合物与用途
CN112584834B (zh) 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物
CN106659761A (zh) 初级癌症疗法后使用的含硼蛋白酶体抑制剂
CN118574622B (zh) Senaparib和替莫唑胺的复方制剂及其制备方法
CN101912399B (zh) 放射线治疗增强剂
CN115124420B (zh) 大黄酸与苦参碱共晶物水合物及制备方法和其组合物与用途
HK1236026B (en) Crystalline tosylate salt of a pi3k delta selective inhibitor for use in pharmaceutical formulations
CA3218977A1 (en) A plurality of tasquinimod particles and use thereof
EA042667B1 (ru) Улучшенные формы селективного ингибитора pi3k-дельта для применения в фармацевтических препаратах
KR20230026415A (ko) 경구 제제 및 이의 용도
HK40110967A (zh) 药物组合物及其用途
WO2019130194A1 (en) Novel drug products of picropodophyllin
EA040951B1 (ru) Лекарственные формы цис-4-[2-{[(3s,4r)-3-фтороксан-4-ил]амино}-8-(2,4,6-трихлоранилино)-9н-пурин-9-ил]-1-метилциклогексан-1-карбоксамида и их применение в способе лечения рака
HK1118704B (en) Radiotherapy enhancer
HK1118807B (en) Potentiator for radiation therapy comprising pyridine derivative as active ingredient